ATMPs in Pharma: Gene, Cell, and Tissue Therapies Explained
ATMPs are classified into three broad types:Click to read the full article.
Advanced Therapy Medicinal Products (ATMPs)
ATMP Manufacturing Failures? Control Strategy and Compliance Solutions
A variety of symptoms can indicate potential failures in ATMP manufacturing. Common failure signals include:Click to read the full article.
Aseptic manipulation deviation during FDA inspection readiness: regulatory risk assessment and CAPA
The initial step in identifying an aseptic manipulation deviation is recognizing symptoms or signals which may manifest in the production environment or laboratory. These signals may not always be direct;…
Cell viability failure during tech transfer: regulatory risk assessment and CAPA
The first step in addressing cell viability failures is to recognize the symptoms or signals that indicate an issue. Common signals may include:Click to read the full article.
Chain of identity breach during scale-up: patient safety impact and disposition
Detecting a chain of identity breach is often initiated by identifying unusual symptoms or signals on the production floor or within the laboratory environment. These could manifest in various forms,…
Chain of identity breach during ATMP manufacturing: inspection-ready investigation package
Recognizing symptoms of a potential chain of identity breach is the first step in your investigation. Symptoms may manifest as discrepancies in documentation, unexpected changes in product characteristics, or reports…
Chain of identity breach during tech transfer: regulatory risk assessment and CAPA
Recognizing symptoms of a Chain of Identity breach during a tech transfer is crucial for early intervention. Potential signs include:Click to read the full article.
Cell viability failure during FDA inspection readiness: patient safety impact and disposition
During routine quality control testing or an internal audit, symptoms signifying a potential cell viability failure may manifest as:Click to read the full article.
Vector potency drift during FDA inspection readiness: inspection-ready investigation package
Identifying symptoms of vector potency drift is the initial step in addressing the issue effectively. These symptoms may manifest as:Click to read the full article.
Cell viability failure during ATMP manufacturing: regulatory risk assessment and CAPA
The first step in addressing cell viability failures is recognizing the symptoms or signals occurring either on the manufacturing floor or in the quality control laboratory. Common indicators include:Click to…
Aseptic manipulation deviation during FDA inspection readiness: patient safety impact and disposition
Identifying symptoms of aseptic manipulation deviations early is key to ensuring patient safety and regulatory compliance. Common signals include:Click to read the full article.
Cryopreservation failure during tech transfer: inspection-ready investigation package
Identifying symptoms of cryopreservation failure during tech transfer is paramount to implementing swift corrective actions. Typical signals may include:Click to read the full article.